In line with high-grade evidence supporting the absence of a link of GLP-1 agonists with pancreatitis, pancreatic cancer, medullary thyroid cancer, or other malignant neoplasms (57–59), STEP trials have reported extremely low rates for acute pancreatitis, no cases of pancreatic cancer, and rates of malignant neoplasms similar with those in placebo group (16, 20, 22, 23, 36). This evidence concerns the gene GCG and familial pancreatic carcinoma.